title: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).
abstract: Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights ( < 40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.
authors.affiliation: Colorado State University, Fort Collins.
authors.forename: P J
authors.initials: PJ
authors.lastname: Bergman
authors.forename: E G
authors.initials: EG
authors.lastname: MacEwen
authors.forename: I D
authors.initials: ID
authors.lastname: Kurzman
authors.forename: C J
authors.initials: CJ
authors.lastname: Henry
authors.forename: A S
authors.initials: AS
authors.lastname: Hammer
authors.forename: D W
authors.initials: DW
authors.lastname: Knapp
authors.forename: A
authors.initials: A
authors.lastname: Hale
authors.forename: S A
authors.initials: SA
authors.lastname: Kruth
authors.forename: M K
authors.initials: MK
authors.lastname: Klein
authors.forename: J
authors.initials: J
authors.lastname: Klausner
authors.forename: A M
authors.initials: AM
authors.lastname: Norris
authors.forename: D
authors.initials: D
authors.lastname: McCaw
authors.forename: R C
authors.initials: RC
authors.lastname: Straw
authors.forename: S J
authors.initials: SJ
authors.lastname: Withrow
mesh_terms: D000671:Amputation, Surgical; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000628:therapy / Q000662:veterinary*; D016190:Carboplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D005260:Female; D008297:Male; D012516:Osteosarcoma / Q000628:therapy / Q000662:veterinary*; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin